Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus

Rocket Pharmaceuticals did not record any revenues in the second quarter of 2026. However, the Zacks Consensus Estimate for the company’s top line was $1 million.

Year to date, shares of Rocket Pharmaceuticals have risen 3.7% compared with the industry’s increase of 6.1%.

Image Source: Zacks Investment Research

RCKT’s Q2 Results in Detail

In the reported quarter, general and administrative expenses declined by around 30.4% year over year to $17.4 million, owing to lower legal expenses and other expenses.

Research and development expenses were $29.5 million, down 30.9% from the year-ago quarter’s figure. The decrease was primarily driven by lower manufacturing and development costs and certain other costs.

As of June 30, 2026, Rocket Pharmaceuticals had cash, cash equivalents and investments of $283.7 million compared with $144.4 million as of March 31, 2026. Management noted that the company’s current cash position reflects the proceeds from the sale of the Rare Pediatric Disease Priority Review Voucher.

RCKT’s Recent Key Updates

In March 2026, the FDA granted accelerated approval to RCKT’s gene therapy Kresladi (marnetegragene autotemcel) to treat patients with severe leukocyte adhesion deficiency-I (LAD-I), an ultra-rare genetic disorder.

Following the nod, Kresladi became the first gene therapy to be approved by the FDA for treating children with severe LAD-I due to biallelic variants in ITGB2 without an available human leukocyte antigen-matched sibling donor for allogeneic hematopoietic stem cell transplant.

Per the company, launch preparations for Kresladi are underway, and patient onboarding is beginning in the fourth quarter of 2026.

Rocket Pharmaceuticals is also developing an investigational gene therapy candidate, RP-A501, in a phase II study for treating patients with Danon disease. RP-A501 is the most advanced AAV-based candidate in the company’s pipeline.

Earlier this month, the company announced positive initial safety findings from the first three patients treated with RP-A501 under a modified Phase 2 protocol for Danon disease. The patients received a recalibrated dose of RP-A501 (3.8 x 10¹³ GC/kg) with a refined immunomodulatory regimen, and no cases of thrombotic microangiopathy, capillary leak syndrome or other significant safety concerns were observed. RCKT is engaging with the FDA to determine the pathway for dosing additional patients and completing the pivotal phase II study, with an update on the regulatory pathway expected in the second half of 2026.

Rocket Pharmaceuticals is also developing RP-A601 in an early-stage study for treating arrhythmogenic cardiomyopathy. The company also plans to start initial patient dosing in a phase I study evaluating another gene therapy candidate, RP-A701, for the treatment of dilated cardiomyopathy in the second half of 2026.

RCKT's Zacks Rank & Stocks to Consider

Rocket Pharmaceuticals currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Repligen RGEN and Liquidia Corporation LQDA, each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.62 during the same time. RGEN shares have declined 0.4% year to date.

Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.

Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $2.97 to $3.02, while estimates for 2027 have increased from $4.81 to $5.31 during the same time. LQDA shares have surged 163.9% year to date.

Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%.

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. 

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research